UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A (RULE 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

Preliminary Proxy Statement 0

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 0

- 0 Definitive Proxy Statement
- Definitive Additional Materials х
- 0 Soliciting Material under §240.14a-12

VIVUS, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required. х 0

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)Title of each class of securities to which transaction applies

(2) Aggregate number of securities to which transaction applies:

- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined)
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

Fee paid previously with preliminary materials

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing

(1)Amount Previously Paid:

(2)	Form, Schedule or Registration Statement No.:
(3)	Filing Party:
(4)	Date Filed:

On June 18, 2013, VIVUS, Inc., or the Company or VIVUS, attended the Wells Fargo Securities Research & Economics 2013 Healthcare Conference and presented the slides attached hereto as Exhibit 1.

Important Additional Information

On June 3, 2013, VIVUS filed a definitive proxy statement and GOLD proxy card with the SEC in connection with the solicitation of proxies for its 2013 Annual Meeting of Stockholders. Stockholders are strongly advised to read VIVUS's 2013 proxy statement because it contains important information. Stockholders may obtain a free copy of the 2013 proxy statement and other documents that the Company files with the SEC from the SEC's website at www.sec.gov or VIVUS's website at www.vivus.com.



FORWARD LOOKING STATEMENT



entation contains "forward looking" statements that involve risks and uncertainties. These statements typically may be identified by the use of This pre forward looking words or phrases such as 'may,' 'believe,' 'expect,' 'forecast,' 'intend,' 'anticipate,' 'predict,' 'should,' 'planned,' 'likely,' 'opportunity,' 'estimated,' and 'potential,' the negative use of these words or other similar words. All forward looking statements included in this document are based on our current expectations, and we assume no obligation to update any such forward looking statements. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward looking statements. In order to comply with the terms of the safe harbor, we note that a variety of factors could cause actual results and experiences to differ materially from the anticipated results or other expectations expressed in such forward looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of our business include but are not limited to: (1) our limited commercial experience with Qsymia@ in the United States, or U.S.; (2) the timing of initiation and completion of the clinical studies required as part of the approval of Qsymia by the U.S. Food and Drug Administration, or FDA; (3) the response from the FDA to the data that VIVUS will submit relating to post-approval clinical studies; (4) the impact of the indicated uses and contraindications contained in the Qsymia label and the Risk Evaluation and Mitigation Strategy, or REMS, requirements: (5) the impact of distribution of Osymia through a certified home delivery pharmacy network; (6) our ability to implement the recently FDA approved amendment to the REMS for Qsymia, which allows dispensing through certified retail pharmacies; (7) that we may be required to provide further analysis of previously submitted clinical trial data; (8) the negative opinion of the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, for the Marketing Authorization Application, or MAA, for Qsymia; (9) whether healthcare providers, payors and public policy makers will recognize the significance of the new AACE guidelines; (10) our ability to successfully commercialize Osymia or establish partnerships for avanafil or Qsymia; (11) the ability of our partners to maintain regulatory approvals to manufacture and adequately supply our products to meet demand; (12) our history of losses and variable quarterly results; (13) substantial competition; (14) risks related to the failure to protect our intellectual property and litigation in which we may become involved; (15) uncertainties of government or third-party payor reimbursement; (16) our reliance on sole source suppliers; (17) our reliance on third parties and our collaborative partners; (18) our failure to continue to develop innovative investigational drug candidates and drugs; (19) risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; (20) our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; (21) the timing of initiation and completion of clinical trials and submissions to foreign authorities; (22) the results of post-marketing studies are not favorable; (23) compliance with post-marketing regulatory standards is not maintained; (24) the volatility and liquidity of the financial markets; (25) our liquidity and capital resources; (26) our expected future revenues, operations and expenditures; and (27) other factors that are described from time to time in our periodic filings with the Securities and Exchange Commission, or the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on February 26, 2013 (as amended by Form 10-K/A, filed with the SEC on April 30, 2013 and by Form 10-K/A, filed with the SEC on June 12, 2013) and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, filed with the SEC on May 8, 2013.

©2013 VIVUS Inc. All rights reserved | www.vivus.com





- · Biopharma company with two FDA approved products in markets with high potential
- Qsymia, the first FDA approved once-daily oral medication for chronic obesity that has demonstrated average weight loss of >10% based on placebo-adjusted data*
 - Obesity is the most prevalent medical condition and represents a large market opportunity
 Qsymia is safe and efficacious
 - * Obesity (2011) DOI: 10.1038/oby.2011.330; The Lancet (2011) DOI: 10.1016/S0140-6736(11)60205-5; Completers Analysis
- Since launch, double digit Qsymia prescription growth
 > 97% quarter-over-quarter prescription growth (4Q2012 to 1Q2013)
- Recent REMS modification to allow access via certified retail pharmacies
 Removes a significant barrier to Osymia commercialization
 - Simplifies prescribing and dispensing
- Improving reimbursement
 - > Qsymia now covered for plans following ESI and Medco National Formularies
 - > Pharmacoeconomic publication to drive additional reimbursement decisions and tools
- STENDRA, next generation PDE5 inhibitor for Erectile Dysfunction with fast onset of action

@2013 VIVUS Inc. All rights reserved | www.vivus.com

INNOVATIVE THERAPIES; NOVEL PRODUCTS



Two approved products in high potential markets:

- Qsymia[®] for chronic weight management
- STENDRA[®]
- STENDRA[™] for erectile dysfunction

VUS

QSYMIA PRESCRIBING INFORMATION





About Qsymia

Qsymia is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.


©2013 VIVUS Inc. All rights reserved | www.vivus.com


Important Safety Information


Qsymia (phentermine and topiramate extendedrelease) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.


The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.













VUS

RETAIL IMPLEMENTATION PLAN ON TRACK FOR MID-JULY 2013

- · Execute wholesaler distribution agreements
- Build distribution network
- · Build and validate REMS-compliant databases
- Enroll, train and certify pharmacies (chain/independent)
- Ship to distribution centers
- · Stock thousands of certified pharmacies

@2013 VIVUS Inc. All rights reserved | www.vivus.com





QSYMIA COVERED BY VA; REDUCES OUT-OF-POCKET COSTS FOR VETERANS




os herein has not been sought or obtained from any party 1




U.S. Department of Veterans Affairs

- Qsymia now available for 3.3 million Veterans Administration (VA) patients for \$9.00 copay
 - > Prevalence of obesity: $\sim 40\%$
 - ➤ Criteria for Use (CFU) consistent with Qsymia label
- 1st U.S. government entity to grant access to Qsymia
 - ➤Conservative institution; evidence-based medicine



COMPLICATIONS-CENTRIC MODEL FOR CARE OF THE OVERWEIGHT/OBESE PATIENT



PUBLICATION OF PHARMACOECONOMIC DATA HELPS REIMBURSEMENT



Thorpe et al. Health Economics Review 2013, \$7 http://www.healtheconomicsreview.com/content/3/1/7

Health Economics Review
 10%-15% weight loss

= gross per capita savings of

Open Access

RESEARCH

The impact of weight loss among seniors on Medicare spending

eth E Thorpe¹, Zhou Yang¹, Kathleen M Long^{2*} and W Timothy Garvey

produced by Qsymia® demonstrated durability

Permission to use the logos herein has not been sought or obtained from any party 17

~\$6,000-\$13,000 over 10 years


overweight with at least one weightrelated comorbidity, lifetime savings could total billions of dollars Study highlighted that weight loss

➤ With ~11.2 million Medicare


patients who are obese or

over two-year treatment period

013 VIVUS Inc. All rights reserved 1 www.v









STENDRA[™] PRESCRIBING INFORMATION





STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwide with the exception of certain Asian Pacific Rim countries. Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure. Tell your healthcare provider about all the medicines you take and discuss your general health status to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.

In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury. STENDRA in combination with other treatments for erectile dysfunction is not recommended. STENDRA does not protect against sexually transmitted diseases, including HIV.

The most common side effects of STENDRA are headache, flushing, runny nose and congestion.

Important Safety Information

2013 VIVUS Inc. All rights reserved | www.vivus.com

<section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>

VIVUS IS WELL-CAPITALIZED TO EXECUTE ON ITS STRATEGY



- \$360MM of new financing secured in the last three months to execute commercialization of Qsymia
 - \$250MM Convertible Senior Unsecured Notes (May 21, 2013)
 - Capped call brings effective conversion price to \$20.00
 - >\$110MM synthetic capped royalty financing (Mar. 26, 2013)
 - \$50MM drawn as of Jun-2013
 - \$60MM remaining through Dec. 31, 2013
- \$406MM of *pro forma* cash and short-term investments at Mar. 31, 2013 reflecting recent financings



IMPORTANT ADDITIONAL INFORMATION

.3 VIVUS Inc. All rights reserved | www.v



On June 3, 2013, VIVUS filed a definitive proxy statement and GOLD proxy card with the SEC in connection with the solicitation of proxies for its 2013 Annual Meeting of Stockholders. Stockholders are strongly advised to read VIVUS's 2013 proxy statement because it contains important information. Stockholders may obtain a free copy of the 2013 proxy statement and other documents that the Company files with the SEC from the SEC's website at www.sec.gov or VIVUS's website at <u>www.vivus.com</u>.

